ATF4 and Miyoshi myopathy: The clinical efficacy of PIs primarily relies on their capacity to trigger transition from adaptive to terminal UPR in MM, through induction of the Activating Transcription Factor 4 (ATF4) and its pro-apoptotic target C/EBP homology protein (CHOP).